Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23918313 | 1.00 | CA12 (0.43) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL23634911 | 1.00 | CA12 (0.43) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL24950539 | 0.89 | CRBN (0.53) | DDB1CRBNGSPT1 | |
| SCHEMBL24939665 | 0.87 | CA12 (0.49) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL24950362 | 0.87 | CA12 (0.44) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL24950355 | 0.87 | CRBN (0.47) | DDB1CRBNBRD4 | |
| SCHEMBL26159209 | 0.85 | CRBN (0.40) | DDB1CRBN | |
| SCHEMBL29323374 | 0.84 | DDB1 (0.47) | DDB1CRBN | |
| SCHEMBL23634974 | 0.84 | CRBN (0.42) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL23634884 | 0.84 | CRBN (0.42) | CA12CA1CA9DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | CRBN, CLNS1A, ADRM1 | CA12 2937/4885CA1 3533/4885CA9 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.